Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes

References

• FahmuellerYNNagelDHoffmannRTImmunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patientsInt J Cancer2013132102349235823047645
   PubMed Web of Science ®Google Scholar
• TesniereASchlemmerFBoigeVImmunogenic death of colon cancer cells treated with oxaliplatinOncogene201029448249119881547
   PubMed Web of Science ®Google Scholar
• GoldenEBPellicciottaIDemariaSBarcellos-HoffMHFormentiSCThe convergence of radiation and immunogenic cell death signaling pathwaysFront Oncol201228822891162
   PubMedGoogle Scholar
• McDermottDLebbeCHodiFSDurable benefit and the potential for long-term survival with immunotherapy in advanced melanomaCancer Treat Rev20144091056106425060490
   PubMed Web of Science ®Google Scholar
• PardollDMImmunology beats cancer: a blueprint for successful translationNat Immunol201213121129113223160205
   PubMed Web of Science ®Google Scholar
• RestifoNPDudleyMERosenbergSAAdoptive immunotherapy for cancer: harnessing the T cell responseNat Rev Immunol201212426928122437939
   PubMed Web of Science ®Google Scholar
• GattinoniLPowellDJJrRosenbergSARestifoNPAdoptive immunotherapy for cancer: building on successNat Rev Immunol20066538339316622476
   PubMed Web of Science ®Google Scholar
• GalonJCostesASanchez-CaboFType, density, and location of immune cells within human colorectal tumors predict clinical outcomeScience200631357951960196417008531
   PubMed Web of Science ®Google Scholar
• MoehlerMGoepfertKHeinrichBOncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1Front Oncol201449224822170
   PubMedGoogle Scholar
• HeinrichBGoepfertKDelicMGallePRMoehlerMInfluence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cellsOnco Targets Ther201361119112723986643
   PubMed Web of Science ®Google Scholar
• BartlettDLLiuZSathaiahMOncolytic viruses as therapeutic cancer vaccinesMol Cancer201312110324020520
   PubMed Web of Science ®Google Scholar
• KoksCAGargADEhrhardtMNewcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell deathInt J Cancer20151365E313E32525208916
   PubMed Web of Science ®Google Scholar
• BreitbachCJParatoKBurkeJHwangTHBellJCKirnDHPexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeuticCurr Opin Virol201513495425900822
   PubMed Web of Science ®Google Scholar
• BreitbachCJThorneSHBellJCKirnDHTargeted and armed oncolytic poxviruses for cancer: the lead example of JX-594Curr Pharm Biotechnol20121391768177221740365
   PubMed Web of Science ®Google Scholar
• KellyERussellSJHistory of oncolytic viruses: genesis to genetic engineeringMol Ther200715465165917299401
   PubMed Web of Science ®Google Scholar
• GuoZSLiuZBartlettDLOncolytic Immunotherapy: dying the right way is a key to eliciting potent antitumor immunityFront Oncol201447424782985
   PubMedGoogle Scholar
• LichtyBDBreitbachCJStojdlDFBellJCGoing viral with cancer immunotherapyNat Rev Cancer201414855956724990523
   PubMed Web of Science ®Google Scholar
• AndtbackaRHIKaufmanHLCollichioFTalimogene laher-parepvec improves durable response rate in patients with advanced melanomaJ Clin Oncol201533252780278826014293
   PubMed Web of Science ®Google Scholar
• BreitbachCJBurkeJJonkerDIntravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humansNature201147773629910221886163
   PubMed Web of Science ®Google Scholar
• KimJHOhJYParkBHSystemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSFMol Ther200614336137016905462
   PubMed Web of Science ®Google Scholar
• ParkBHHwangTLiuTCUse of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trialLancet Oncol20089653354218495536
   PubMed Web of Science ®Google Scholar
• HeoJReidTRuoLRandomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerNat Med201319332933623396206
   PubMed Web of Science ®Google Scholar
• KimMKBreitbachCJMoonAOncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humansSci Transl Med20135185185ra163
   Web of Science ®Google Scholar
• BreitbachCJArulanandamRDe SilvaNOncolytic vaccinia virus disrupts tumor-associated vasculature in humansCancer Res20137341265127523393196
   PubMed Web of Science ®Google Scholar
• ParatoKABreitbachCJLe BoeufFThe oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancersMol Ther201220474975822186794
   PubMed Web of Science ®Google Scholar
• FoloppeJKintzJFutinNTargeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virusGene Ther200815201361137118480846
   PubMedGoogle Scholar
• ErbsPRegulierEKintzJIn vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion geneCancer Res200060143813382210919655
   PubMed Web of Science ®Google Scholar
• FendLRemy-ZillerCFoloppeJOncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironmentOncoimmunology201552e108041427057460
   PubMedGoogle Scholar
• MoehlerMHZeidlerMWilsbergVParvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cellsHum Gene Ther2005168996100516076257
   PubMed Web of Science ®Google Scholar
• WolfelTHauerMKlehmannEAnalysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL)Int J Cancer19935522372447690346
   PubMedGoogle Scholar
• WolfelTKlehmannEMullerCSchuttKHMeyer zum BuschenfeldeKHKnuthALysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigensJ Exp Med198917037978102788708
   PubMedGoogle Scholar
• WolfelTVan PelABrichardVTwo tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytesEur J Immunol19942437597648125142
   PubMedGoogle Scholar
• LunXChanJZhouHEfficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of gliomaMol Ther201018111927193620808290
   PubMed Web of Science ®Google Scholar
• CasaresNPequignotMOTesniereACaspase-dependent immunogenicity of doxorubicin-induced tumor cell deathJ Exp Med2005202121691170116365148
   PubMed Web of Science ®Google Scholar
• VermesIHaanenCSteffens-NakkenHReutelingspergerCA novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin VJ Immunol Methods1995184139517622868
   PubMed Web of Science ®Google Scholar
• LehnerJWittwerCFerschingDSiegeleBHoldenriederSStoetzerOJMethodological and preanalytical evaluation of an HMGB1 immunoassayAnticancer Res20123252059206222593488
   PubMed Web of Science ®Google Scholar
• MartinsIWangYMichaudMMolecular mechanisms of ATP secretion during immunogenic cell deathCell Death Differ2014211799123852373
   PubMed Web of Science ®Google Scholar
• KroemerGGalluzziLKeppOZitvogelLImmunogenic cell death in cancer therapyAnnu Rev Immunol201331517223157435
   PubMed Web of Science ®Google Scholar
• KeppOTesniereASchlemmerFImmunogenic cell death modalities and their impact on cancer treatmentApoptosis200914436437519145485
   PubMed Web of Science ®Google Scholar
• PanaretakisTKeppOBrockmeierUMechanisms of pre-apoptotic calreticulin exposure in immunogenic cell deathEMBO J200928557859019165151
   PubMed Web of Science ®Google Scholar
• ZitvogelLApetohLGhiringhelliFKroemerGImmunological aspects of cancer chemotherapyNat Rev Immunol200881597318097448
   PubMed Web of Science ®Google Scholar
• ZieglerSFRamsdellFAldersonMRThe activation antigen CD69Stem Cells19941254564657804122
   PubMed Web of Science ®Google Scholar
• AktasEKucuksezerUCBilgicSErtenGDenizGRelationship between CD107a expression and cytotoxic activityCell Immunol2009254214915418835598
   PubMed Web of Science ®Google Scholar
• LuskyMErbsPFoloppeJAcresRBOncolytic vaccinia virus: a silver bullet?Expert Rev Vaccines20109121353135621105770
   PubMed Web of Science ®Google Scholar
• ErbsPFindeliAKintzJModified vaccinia virus Ankara as a vector for suicide gene therapyCancer Gene Ther2008151182817992203
   PubMedGoogle Scholar
• VermesAGuchelaarHJDankertJFlucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactionsJ Antimicrob Chemother200046217117910933638
   PubMed Web of Science ®Google Scholar
• KuluYKawasakiHDonahueJMConcurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysisCancer Gene Ther201320213314023348635
   PubMed Web of Science ®Google Scholar
• Ottolino-PerryKDialloJ-SLichtyBDBellJCAndrea McCartJIntelligent design: combination therapy with oncolytic virusesMol Ther2010182251263
   PubMed Web of Science ®Google Scholar
• SauterBAlbertMLFranciscoLLarssonMSomersanSBhardwajNConsequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cellsJ Exp Med2000191342343410662788
   PubMed Web of Science ®Google Scholar
• GreenDRFergusonTZitvogelLKroemerGImmunogenic and tolerogenic cell deathNat Rev Immunol20099535336319365408
   PubMed Web of Science ®Google Scholar
• Vanden BergheTKalaiMDeneckerGMeeusASaelensXVandenabeelePNecrosis is associated with IL-6 production but apoptosis is notCell Signal200618332833516023831
   PubMed Web of Science ®Google Scholar
• BergheTVLinkermannAJouan-LanhouetSWalczakHVandenabeelePRegulated necrosis: the expanding network of non-apoptotic cell death pathwaysNat Rev Mol Cell Biol201415213514724452471
   PubMed Web of Science ®Google Scholar
• GuoZSNaikAO’MalleyMEThe enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2Cancer Res200565219991999816267024
   PubMed Web of Science ®Google Scholar
• MoehlerMBlechaczBWeiskopfNEffective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectorsCancer Gene Ther20018315816711332986
   PubMed Web of Science ®Google Scholar
• SagaKKanedaYOncolytic Sendai virus-based virotherapy for cancer: recent advancesOncolytic Virother2015414114727512677
   PubMed Web of Science ®Google Scholar
• HuangHXiaoTHeLJiHLiuXYInterferon-beta-armed oncolytic adenovirus induces both apoptosis and necroptosis in cancer cellsChin J Biochem Biophys2012449737745
   Google Scholar
• AngelovaALGrekovaSPHellerAComplementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancerJ Virol201488105263527624574398
   PubMed Web of Science ®Google Scholar
• GargADKryskoDVVerfaillieTA novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell deathEMBO J20123151062107922252128
   PubMed Web of Science ®Google Scholar
• KryskoDVGargADKaczmarekAKryskoOAgostinisPVandenabeelePImmunogenic cell death and DAMPs in cancer therapyNat Rev Cancer2012121286087523151605
   PubMed Web of Science ®Google Scholar
• WorkenheSTPolJGLichtyBDCummingsDTMossmanKLCombining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacyCancer Immunol Res20131530931924777969
   PubMed Web of Science ®Google Scholar
• SimpsonGRRelphKHarringtonKMelcherAPandhaHCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesOncolytic Virother2016511327579292
   PubMedGoogle Scholar
• CellaMSallustoFLanzavecchiaAOrigin, maturation and antigen presenting function of dendritic cellsCurr Opin Immunol19979110169039784
   PubMed Web of Science ®Google Scholar
• CellaMEngeringAPinetVPietersJLanzavecchiaAInflammatory stimuli induce accumulation of MHC class II complexes on dendritic cellsNature199738866447827879285591
   PubMed Web of Science ®Google Scholar
• BanchereauJSteinmanRMDendritic cells and the control of immunityNature199839266732452529521319
   PubMed Web of Science ®Google Scholar
• ChanCWHousseauFThe ‘kiss of death’ by dendritic cells to cancer cellsCell Death Differ2008151586917948029
   PubMed Web of Science ®Google Scholar
• BasuSBinderRJSutoRAndersonKMSrivastavaPKNecrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathwayInt Immunol200012111539154611058573
   PubMed Web of Science ®Google Scholar
• PasparakisMVandenabeelePNecroptosis and its role in inflammationNature2015517753431132025592536
   PubMed Web of Science ®Google Scholar
• EngelmayerJLarssonMSubkleweMVaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasionJ Immunol1999163126762676810586075
   PubMed Web of Science ®Google Scholar
• YaoYLiPSinghPVaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class IICell Immunol200724629210217678637
   PubMedGoogle Scholar
• YatesNLAlexander-MillerMAVaccinia virus infection of mature dendritic cells results in activation of virus-specific naive CD8+ T cells: a potential mechanism for direct presentationVirology2007359234936117056088
   PubMedGoogle Scholar
• QinHChatterjeeSKCancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSFHum Gene Ther1996715185318608894677
   PubMedGoogle Scholar
• BoozariBMundtBWollerNAntitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinomaGut201059101416142620675696
   PubMed Web of Science ®Google Scholar
• LindseyWBLowdellMWMartiGECD69 expression as an index of T-cell function: assay standardization, validation and use in monitoring immune recoveryCytotherapy20079212313217453964
   PubMed Web of Science ®Google Scholar
• BettsMRBrenchleyJMPriceDASensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulationJ Immunol Methods20032811–2657814580882
   PubMed Web of Science ®Google Scholar
• RajaniKParrishCKottkeTCombination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responsesMol Ther201624116617426310630
   PubMed Web of Science ®Google Scholar
• AndtbackaRHICollichioFAAmatrudaTOPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanomaJ Clin Oncol201331 abstrLBA9008
   PubMedGoogle Scholar
• PuzanovIMilhemMAndtbackaRPhase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanomaJ Immunother Cancer20131suppl 184
   Google Scholar
• EngelandCEGrossardtCVeinaldeRCTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapyMol Ther201422111949195925156126
   PubMed Web of Science ®Google Scholar
• Yuan QuahMWongYAndtbackaRAuGShafrenDRAbstract 2341: Elevated immune activity following an anticancer combination therapy of a novel oncolytic immunotherapeutic agent, CAVATAK (Coxsackievirus A21), and immune checkpoint blockadeCancer research7614 Supplement23412016
   Google Scholar
• RojasJJSampathPHouWThorneSHDefining effective combinations of immune checkpoint blockade and oncolytic virotherapyClin Cancer Res201521245543555126187615
   PubMed Web of Science ®Google Scholar